These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 2239486

  • 1. Levodopa treatment of Parkinson's syndrome: past and future.
    Pletscher A.
    Adv Neurol; 1990; 53():469-73. PubMed ID: 2239486
    [No Abstract] [Full Text] [Related]

  • 2. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
    Meco G, Casacchia M, Zamponi A, Agnoli A.
    Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
    [No Abstract] [Full Text] [Related]

  • 3. [Our experience in the treatment of Parkinson's disease with L-dopa plus RO 4-4602 combination].
    Campanella G, Pennetta R.
    Acta Neurol (Napoli); 1974; 29(3):252-63. PubMed ID: 4417098
    [No Abstract] [Full Text] [Related]

  • 4. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M, Barba C, Ruggieri S, Zamponi A, Agnoli A.
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract] [Full Text] [Related]

  • 5. [CB 154 in the treatment of parkinson's disease--results of the association with L-DOPA + DDI (author's transl)].
    Meco G, Casacchia M, Zamponi A, Agnoli A.
    Schweiz Rundsch Med Prax; 1976 May 04; 65(18):557-9. PubMed ID: 989900
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacological approaches to Parkinson's disease in the different phases of evolution.
    Giovannini P, Piccolo I, Scigliano G, Caraceni T.
    J Neural Transm Suppl; 1986 May 04; 22():173-87. PubMed ID: 3097255
    [Abstract] [Full Text] [Related]

  • 7. Parkinson's disease.
    Lieberman AN.
    Compr Ther; 1986 Mar 04; 12(3):25-9. PubMed ID: 3486090
    [No Abstract] [Full Text] [Related]

  • 8. [Development of studies on the treatment of Parkinson syndromes using levodopa. I. Short- and medium-term (2 years) effects of the combination levodopa decarboxylase inhibitor].
    Rondot P, Ribadeau Dumas JL, Cardon P.
    Therapie; 1975 Mar 04; 30(5):653-66. PubMed ID: 769245
    [No Abstract] [Full Text] [Related]

  • 9. [L-dopa therapy of parkinson syndrome].
    Kapfhammer HP, Kuss HJ, Rüther E.
    Nervenarzt; 1985 Feb 04; 56(2):57-68. PubMed ID: 3920542
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
    Fermaglich J.
    Med Ann Dist Columbia; 1974 Dec 04; 43(12):587-91. PubMed ID: 4532167
    [No Abstract] [Full Text] [Related]

  • 11. [Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
    Rondot P, Ziegler M, Aymard N, Holzer J.
    Rev Neurol (Paris); 1987 Dec 04; 143(11):746-52. PubMed ID: 3324265
    [Abstract] [Full Text] [Related]

  • 12. MAO type B inhibitors as adjunct to L-dopa therapy.
    Youdim MB, Finberg JP.
    Adv Neurol; 1987 Dec 04; 45():127-36. PubMed ID: 3103383
    [No Abstract] [Full Text] [Related]

  • 13. Levodopa therapy in Parkinson's disease.
    Koller WC, Hubble JP.
    Neurology; 1990 Oct 04; 40(10 Suppl 3):suppl 40-7; discussion 47-9. PubMed ID: 2215973
    [No Abstract] [Full Text] [Related]

  • 14. Long-term course in Parkinson's syndrome and cerebral polypathy (Parkinson plus).
    Fischer PA.
    Adv Neurol; 1987 Oct 04; 45():235-8. PubMed ID: 3825695
    [No Abstract] [Full Text] [Related]

  • 15. [The L-dopa test in Parkinson's disease].
    Esteguy M, Bonnet AM, Kefalos J, Lhermitte F, Agid Y.
    Rev Neurol (Paris); 1985 Oct 04; 141(5):413-5. PubMed ID: 4048732
    [Abstract] [Full Text] [Related]

  • 16. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P.
    Rev Prat; 1974 Mar 11; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract] [Full Text] [Related]

  • 17. Dopa-unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP?
    Imai H, Nakamura T, Kondo T, Narabayashi H.
    Adv Neurol; 1993 Mar 11; 60():622-5. PubMed ID: 8420201
    [No Abstract] [Full Text] [Related]

  • 18. Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
    Kostić VS, Covicković-Sternić N.
    Neurologija; 1990 Mar 11; 39(2):99-105. PubMed ID: 2267052
    [Abstract] [Full Text] [Related]

  • 19. Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
    Rinne UK, Marttila R.
    Ann Neurol; 1978 Sep 11; 4(3):263-7. PubMed ID: 718139
    [Abstract] [Full Text] [Related]

  • 20. Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
    Birkmayer W, Birkmayer GD.
    J Neural Transm Suppl; 1986 Sep 11; 22():219-25. PubMed ID: 3097256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.